Protalix BioTherapeutics, Inc. (PLX) Total Return Calculator with Dividends Reinvested

Protalix BioTherapeutics, Inc.

Popular:

The total return for Protalix BioTherapeutics, Inc. (PLX) stock is +46.41% over the past 12 months. So far it's up 28.74% this year. The 5-year total return is +14.87%, meaning $10,000 invested in PLX stock 5 years ago would be worth $11,487 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in PLX 1 year ago, it would be worth $15,878 today — you'd have gained $5,878.

With Dividends Reinvested$15,878+58.78%

Price Only (No DRIP)$15,878+58.78%

Period2025-06-30 → 2026-06-29

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in PLX

1Y$14,641+$4,641 (+46.4%)46.4% CAGR

3Y$10,182+$182 (+1.8%)0.6% CAGR

5Y$11,487+$1,487 (+14.9%)2.8% CAGR

10Y$3,270-$6,730 (-67.3%)-10.6% CAGR

15Y$361-$9,639 (-96.4%)-19.9% CAGR

20Y$44-$9,956 (-99.6%)-23.7% CAGR

30Y$26-$9,974 (-99.7%)-18.0% CAGR

Protalix BioTherapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading PLX total return...

As of 2026-06-30

Performance Summary

Best Year+2025.00%2005

Worst Year-87.48%2007

Max Drawdown-39.68%2026-02-19 → 2026-05-19

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+28.74%	—	+35.06%	—	$12,874
1Y	+46.41%	46.41%	+58.78%	—	$14,641
3Y	+1.82%	0.60%	+8.30%	—	$10,182
5Y	+14.87%	2.81%	+23.04%	—	$11,487
10Y	-67.30%	-10.58%	-63.73%	—	$3,270
15Y	-96.39%	-19.86%	-96.23%	—	$361
20Y	-99.56%	-23.73%	-99.53%	—	$44
30Y	-99.74%	-17.96%	-99.72%	—	$26

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+65.52%	+65.52%	—	+0.41%	+65.1pp
2025	-8.63%	-8.63%	—	+16.64%	-25.3pp
2024	+3.30%	+3.30%	—	+24.00%	-20.7pp
2023	+29.93%	+29.93%	—	+24.81%	+5.1pp
2022	+50.55%	+50.55%	—	-19.95%	+70.5pp

PLX outperformed the S&P 500 by 25.56pp over the past year (+46.41% vs +20.84%).

Loading summary...

PLX Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
PLXProtalix BioTherapeutics, Inc.	$189M	+11.4%	+28.7%	+46.4%	—	+1.8%	+14.9%	-67.3%
RAREUltragenyx Pharmaceutical Inc.	$3.0B	+28.2%	+23.3%	-21.7%	—	-40.1%	-68.8%	-40.8%
FOLDAmicus Therapeutics, Inc.	$4.5B	—	+1.5%	+153.8%	—	+20.0%	+41.4%	+165.9%
SRPTSarepta Therapeutics, Inc.	$1.8B	-4.8%	-21.7%	-12.0%	—	-84.6%	-79.0%	-9.9%
ACADACADIA Pharmaceuticals Inc.	$4.3B	+16.3%	-10.7%	+4.2%	—	-2.1%	-6.6%	-25.7%
KRYSKrystal Biotech, Inc.	$11.1B	+22.4%	+40.8%	+142.0%	—	+199.8%	+416.5%	+3167.2%
PTCTPTC Therapeutics, Inc.	$6.8B	+10.5%	+10.0%	+70.1%	—	+108.9%	+91.2%	+1167.4%
BMRNBioMarin Pharmaceutical Inc.	$11.1B	+0.7%	-3.6%	+4.8%	—	-37.9%	-31.6%	-25.6%
HALOHalozyme Therapeutics, Inc.	$9.2B	+16.0%	+1.2%	+32.0%	—	+104.2%	+56.2%	+743.0%
IONSIonis Pharmaceuticals, Inc.	$13.3B	+5.5%	-4.0%	+93.0%	—	+95.7%	+99.1%	+248.3%
LGNDLigand Pharmaceuticals Incorporated	$6.3B	+35.4%	+49.9%	+141.0%	—	+294.3%	+110.8%	+154.9%

Compare:PLX vs RARE PLX vs FOLD PLX vs SRPT PLX vs RARE vs FOLD

About PLX Dividend Returns

Protalix BioTherapeutics, Inc. (PLX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of PLX over the past year?

Protalix BioTherapeutics, Inc. (PLX) delivered a return of 46.41% over the past year. Since PLX does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in PLX be worth today?

A $10,000 investment in Protalix BioTherapeutics, Inc. one year ago would be worth $14,641 today, representing a gain of $4,641.

Q3Does PLX pay dividends?

Protalix BioTherapeutics, Inc. (PLX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For PLX, the total return equals the price-only return.

Q4Did PLX beat the S&P 500?

Yes, Protalix BioTherapeutics, Inc. (PLX) outperformed the S&P 500 by 25.56 percentage points over the past year. PLX delivered a total return of 46.41%, compared to the S&P 500's 20.84%. This 25.56pp alpha means investors in PLX earned more than a passive S&P 500 index fund.

Q5What is PLX's worst drawdown?

Protalix BioTherapeutics, Inc. (PLX) experienced a maximum drawdown of -39.68% over the past year, declining from its peak on 2026-02-19 to its trough on 2026-05-19. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is PLX's long-term total return over 10, 20, or 30 years?

Here are Protalix BioTherapeutics, Inc. (PLX)'s long-term returns with dividends reinvested. Over 10 years, the total return is -67.3% (-10.6% CAGR) — $10,000 would have grown to $3,270. Over 20 years: -99.6% total return (-23.7% CAGR) — $10,000 → $44. Over 30 years: -99.7% total return (-18.0% CAGR) — $10,000 → $26. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was PLX's best and worst year?

Protalix BioTherapeutics, Inc.'s best calendar year was 2005 with a total return of 2025.0%. Its worst year was 2007 with a total return of -87.5%. This range shows the volatility investors should expect — the difference between the best and worst year is 2112.5 percentage points.

How much would $100/month in PLX be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →